Cardiovascular disease remains the leading cause of death globally. So when researchers began investigating Ganoderma lucidum for heart health markers — blood pressure, cholesterol, antioxidant status — the hope was that a safe, well-tolerated mushroom might offer meaningful cardiovascular support.
The results have been mixed. Some studies show clear effects. The largest systematic review reached a more cautious conclusion. Understanding both is essential to making an informed decision.
Blood Pressure: Triterpenes and ACE Inhibition
Ganoderma triterpenes — particularly ganoderic acids — have been shown in laboratory studies to inhibit angiotensin-converting enzyme (ACE), the same target as widely prescribed ACE-inhibitor blood pressure medications. The mechanism: ganoderic acids bind to the active site of the ACE enzyme, reducing its ability to convert angiotensin I to angiotensin II — a potent vasoconstrictor that raises blood pressure.
Several animal studies have reported modest but statistically significant blood pressure reductions following Ganoderma administration. The effect size is smaller than pharmaceutical ACE inhibitors — typically a 5–10 mmHg reduction in systolic pressure — consistent with the lower potency of natural compounds.
Human data is limited. A few small clinical studies have reported blood pressure reductions in hypertensive patients taking Ganoderma, but none were large enough or rigorous enough to establish efficacy. The 2015 Cochrane review (discussed below) explicitly noted the insufficiency of the blood pressure data.
Cholesterol and Lipid Profiles
The cholesterol data is somewhat stronger than the blood pressure data but still not definitive. Key findings across multiple studies include:
- LDL cholesterol reduction. Several trials have reported reductions in LDL ("bad") cholesterol ranging from 5–15%, with the effect generally more pronounced in people with elevated baseline levels.
- HDL cholesterol. Some studies show a modest increase in HDL ("good") cholesterol, though this finding is less consistent than the LDL data.
- Triglycerides. Results are mixed — some studies show reductions, others show no effect. The variability may reflect differences in study design, Ganoderma preparation, and participant characteristics.
- Antioxidant protection of LDL. Even when total LDL levels are not dramatically reduced, several studies have documented that Ganoderma's antioxidant compounds reduce LDL oxidation — a process that makes LDL particles more atherogenic (plaque-forming). This is a distinct mechanism from simply lowering total LDL.
The Cochrane Review: A Necessary Reality Check
In 2015, the Cochrane Collaboration — widely considered the gold standard for evidence-based medicine — published a systematic review titled "Ganoderma lucidum for treating cardiovascular risk factors." After analyzing five randomized controlled trials with a total of 398 participants, the review concluded:
"G lucidum was not an effective treatment for reducing blood glucose, blood pressure, or cholesterol. It was not clear whether G lucidum might reduce blood glucose, blood pressure, or cholesterol over longer periods."
This is the largest and most rigorous analysis of the cardiovascular data, and it must be acknowledged honestly. The review did not say Ganoderma is useless — it said the evidence was insufficient to demonstrate efficacy for these endpoints. The distinction matters.
However, the Cochrane review also had important limitations: the included trials were small, used different Ganoderma preparations and dosages, and were of relatively short duration. A negative result in this context means "not proven" rather than "disproven." Since 2015, additional studies have been published that were not included in the review, though none have been large enough to fundamentally change the evidence picture.
Mechanism: Why Researchers Keep Looking
Despite the Cochrane review's cautious conclusion, there are biologically plausible reasons why Ganoderma might influence cardiovascular health:
| Mechanism | Relevant Compound | Evidence Strength |
|---|---|---|
| ACE inhibition | Ganoderic acids (triterpenes) | In-vitro; limited human data |
| HMG-CoA reductase inhibition (similar to statins) | Triterpenoids, sterols | In-vitro; modest human signal |
| Antioxidant protection of LDL | Polysaccharides, phenolic compounds | In-vitro; some human data |
| Anti-platelet aggregation | Adenosine, triterpenes | In-vitro; clinically relevant interaction risk |
| Endothelial function improvement | Polysaccharides | Animal models; no human data |
An Important Safety Note: Blood Thinners
Ganoderma contains compounds with anti-platelet activity — meaning they can reduce blood clotting. For most people, this is benign. For people taking warfarin (Coumadin), clopidogrel (Plavix), aspirin, or any anticoagulant or antiplatelet medication, this becomes a clinically relevant interaction risk.
There are case reports of elevated INR (a measure of blood clotting time) in patients taking warfarin who also consumed Reishi. Anyone on blood-thinning medication should discuss Reishi use with their prescribing physician before starting — and should have their clotting parameters monitored if they decide to proceed.
Common Questions
Can Reishi lower my blood pressure?
Laboratory studies show ACE-inhibitory activity, and some small human trials have reported modest blood pressure reductions. However, the Cochrane review found insufficient evidence to confirm this effect. Reishi should not be used as a substitute for prescribed antihypertensive medication.
Can I take Reishi with my statin?
There are no well-documented interactions between Ganoderma and statins. However, because both may influence liver function, anyone taking a statin should inform their doctor about Reishi use so that liver enzyme monitoring can account for all variables.
Is Reishi a blood thinner?
It has mild anti-platelet effects, meaning it can reduce the tendency of blood to clot. This is not the same as being a "blood thinner" in the pharmaceutical sense, but it is potent enough to warrant caution with anticoagulant medications. If you are scheduled for surgery, most healthcare providers recommend discontinuing Reishi at least two weeks beforehand.
The Bottom Line
The cardiovascular evidence for Ganoderma lucidum is less robust than the liver or immune research. The Cochrane review — the most authoritative analysis available — concluded the evidence was insufficient for the primary cardiovascular endpoints. That said, the mechanistic plausibility is real (ACE inhibition, lipid effects, antioxidant protection), and smaller studies continue to report positive signals that warrant larger, better-designed trials.
For individuals interested in general cardiovascular wellness, Ganoderma may offer supportive benefits — particularly through its anti-inflammatory and antioxidant mechanisms. For individuals with diagnosed cardiovascular disease or those on blood-thinning medications, caution and physician consultation are non-negotiable.
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. The studies cited are for informational and educational purposes only. Always consult your healthcare provider before adding any supplement to your regimen, especially if you have cardiovascular disease or are taking blood-thinning medications.